Karuna Therapeutics
NEWS
2022 featured pivotal data that could change the landscape in non-alcoholic steatohepatitis, Alzheimer’s disease, sickle cell disease and many more indications.
Karuna Therapeutics appointed Bill Meury as its new president and chief executive officer, succeeding its current head, Steve Paul.
Karuna Therapeutics released results from the Phase III EMERGENT-2 trial showing that KarXT, its lead candidate, can strongly reduce symptom severity in schizophrenia patients.
Zai Lab, a China-focused biopharma company that focuses on treatments for cancer and autoimmune diseases, announced positive data for its clinical trial on Zejula (niraparib) for ovarian cancer.
First Moscow State Medical University has paused recruiting new patients for its ongoing clinical trials following a disruption in the university’s ability to receive clinical trial samples.
On Sunday, Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country.
The company is working on developing therapies for neuropsychiatric diseases. Karuna is expecting data from a Phase II clinical trial later this year of KarXT xanomeline/trospium chloride, a muscarinic receptor modulator, to treat acute psychosis associated with schizophrenia.
Two of this week’s biotech startup initial public offerings, BridgeBio and Adaptive Biotechnologies, have market values exceeding the magic $1 billion mark, and have recently launched initial public offerings (IPOs), but also increased their fundraising goals.
Four biotech companies recently filed with the U.S. Securities and Exchange Commission their plans for initial public offerings (IPO). Let’s take a look.
JOBS
IN THE PRESS